Helping smokers quit remains one of the biggest opportunities to reduce tobacco-related disease. New recommendations urge healthcare professionals to include nicotine e-cigarettes among the evidence-based cessation options discussed with adult patients, while acknowledging that long-term safety data remain limited.
E-cigarettes should be part of discussions between doctors and patients about how to stop smoking, according to new guidance published in Jama.
Cigarette smoking kills nearly half a million Americans each year, yet most people who smoke are unable to quit despite multiple attempts. Helping more people to quit smoking remains one of the greatest opportunities to reduce tobacco-related disease and death.
An interdisciplinary group of tobacco treatment experts is urging clinicians to broaden the treatment options they discuss with patients who want to stop smoking cigarettes.
In new recommendations published in Jama, the researchers outline how clinicians can incorporate nicotine e-cigarettes as part of patient-centered conversations about smoking cessation. The goal is not to encourage nicotine use but to help more people to stop smoking combustible cigarettes — the leading cause of preventable death in the U.S.
Developed by the Harm Reduction Work Group of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the recommendations provide clinicians with practical guidance for discussing smoking cessation. Rather than taking a one-size-fits-all approach, the authors encourage clinicians to present patients with a “menu of options” for quitting and work with them to weigh the risks and benefits.
The paper also includes a conversation guide that walks clinicians through key questions to consider, strategies for addressing common misconceptions and evidence-based recommendations for counseling patients who choose to use nicotine e-cigarettes.
“We’ve had clinicians asking us for years how they should talk to their patients about e-cigarettes, and we really didn’t have anywhere to point them,” said Alana Rojewski, Ph.D., associate director of the Tobacco Treatment Program at Musc Hollings Cancer Center. “There was plenty of research literature but nothing that offered practical guidance on how to have these conversations in clinical practice.”
A Patient-Centered Approach to Quitting Smoking
“The main takeaway is for clinicians to include e-cigarettes in their toolkit of smoking cessation options,” said Tracy Smith, Ph.D., an addiction scientist and co-leader of the Cancer Prevention and Control Research Program at Hollings.
The authors emphasize that the best approach to quitting smoking will vary from person to person and should be tailored to each patient’s goals, preferences and medical needs.
“There isn’t a one-size-fits-all approach to quitting,” Smith added. “Our job is to provide patients with accurate information and a menu of evidence-based options that give them the best chance of success.”
A major point of emphasis is on shared decision-making between clinicians and patients. If a patient has no preference about treatment options, smoking cessation medications already approved by the U.S. Food and Drug Administration (FDA) remain an appropriate place to start. However, if a patient prefers to try nicotine e-cigarettes, clinicians should support that decision rather than requiring them to try and fail other therapies first.
That recommendation reflects a stark reality: Continuing to smoke cigarettes carries significant health risks, and delaying treatment can have serious consequences.
“Time is of the essence when we’re trying to get people off cigarettes,” Smith said. “The priority is helping people quit combustible cigarettes as quickly and effectively as possible.”
That message is particularly important for people whose health is already affected by smoking, including cancer survivors and people living with cardiovascular disease or other chronic illnesses.
Importantly, the recommendations are intended only for adults who currently smoke cigarettes. The authors explicitly state that nicotine e-cigarettes should not be used by youth or people who have never used tobacco products.
Another major goal of the paper is correcting misconceptions about nicotine e-cigarettes among both patients and providers. The researchers note that public perceptions of nicotine e-cigarettes have become increasingly negative despite growing evidence supporting their use as smoking cessation tools.
One of the most common misconceptions is that nicotine itself is responsible for smoking-related diseases, such as cancer and heart disease. In reality, most smoking-related illnesses are caused by the toxic chemicals produced when tobacco is burned, not nicotine itself.
Because e-cigarettes do not involve combustion, they expose users to substantially fewer harmful chemicals. The paper cites high-certainty evidence from Cochrane systematic reviews showing that nicotine e-cigarettes can be more effective than nicotine replacement therapies, such as patches and gum, at helping people to stop smoking. Other reviews have similarly found that their effectiveness is comparable to FDA-approved smoking cessation medications.
Date: 08.12.2025
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.
But that does not mean nicotine e-cigarettes are risk-free.
“The evidence for helping people quit smoking is pretty good, but they’re not a magic bullet,” Smith said. “There are lots of people who try e-cigarettes for whom they don’t work or who end up using both products for a prolonged period of time. Like every smoking cessation treatment, there are risks and benefits that patients and clinicians should discuss together.”
Researchers also acknowledge that safety data on nicotine e-cigarettes are still limited. While e-cigarettes have been available for years, scientists will need decades of additional research to understand their long-term health effects fully.
“The lack of long-term safety data is a potential risk,” Rojewski said. “But helping people transition away from combustible cigarettes is what’s most important. The sooner we can help someone quit, the better. Every conversation about smoking cessation is an opportunity to improve someone’s health and reduce their risk of developing smoking-related disease.”
Practical Guidance for Clinicians
Beyond recommending that clinicians discuss nicotine e-cigarettes with patients who smoke, the paper offers practical recommendations for doing so. Those recommendations encourage clinicians to:
Recommend FDA-authorized nicotine e-cigarette products when appropriate.
Ask key questions to understand a patient’s goals, preferences and treatment history.
Support patients in completely transitioning away from cigarettes as soon as possible.
Incorporate behavioral counseling and follow-up care into treatment plans.
Behavioral counseling remains a critical component of treatment, regardless of the smoking cessation strategy. Combining counseling with medication has long been the gold standard. Through counseling, patients can identify smoking triggers, set quit goals and develop strategies for navigating everyday situations that may increase the urge to smoke.
“Smoking isn’t just nicotine dependence — it’s also a learned behavior that’s woven throughout people’s daily lives,” Rojewski explained. “People often smoke when they drink their morning coffee, drive to work or cope with stress. Quitting requires relearning those behaviors and developing new habits that support long-term success.”
Supporting Patients Through Research and Treatment
The recommendations align closely with the patient-centered approach already used by the Musc Health Tobacco Treatment Program. The program provides evidence-based counseling and medications while tailoring treatment plans to individual patients.
The paper also highlights the collaborative tobacco research efforts at Hollings. Multiple investigators from the center’s Tobacco Research Group, including Smith; Rojewski; Mariel Bello, Ph.D.; Matthew Carpenter, Ph.D.; and Erin McClure, Ph.D., contributed their expertise in tobacco treatment, nicotine dependence, harm reduction and cancer prevention.
These new recommendations are one example of how years of tobacco research are being translated into evidence-based guidance that clinicians can use to support patients. Ultimately, the recommendations are intended to help clinicians to have more informed and nuanced conversations about smoking cessation while keeping the focus on what matters most: helping people to quit cigarettes.
“Our goal isn’t to recommend one product over another,” Rojewski said. “It’s to give clinicians the tools they need to have patient-centered conversations that get smokers closer to quitting.”
Original Article: Nicotine E-Cigarettes for Cigarette Smoking Cessation: Recommendations to US-Based Clinicians; Jama; DOI:10.1001/Jama.2026.13087